California State Teachers Retirement System boosted its stake in shares of Tocagen Inc (NASDAQ:TOCA) by 103.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 28,070 shares of the company’s stock after purchasing an additional 14,270 shares during the quarter. California State Teachers Retirement System’s holdings in Tocagen were worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently added to or reduced their stakes in TOCA. BlackRock Inc. boosted its position in Tocagen by 36.4% during the fourth quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock worth $10,960,000 after purchasing an additional 285,396 shares during the period. JPMorgan Chase & Co. boosted its position in Tocagen by 52.9% during the third quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock worth $7,886,000 after purchasing an additional 218,100 shares during the period. Pure Financial Advisors Inc. bought a new position in Tocagen during the fourth quarter worth $1,324,000. Artal Group S.A. bought a new position in Tocagen during the fourth quarter worth $1,025,000. Finally, State Street Corp bought a new position in Tocagen during the second quarter worth $1,083,000. 32.78% of the stock is owned by hedge funds and other institutional investors.
TOCA has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. BidaskClub raised shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Finally, ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $21.50.
Shares of Tocagen stock opened at $10.99 on Monday. The stock has a market capitalization of $218.83 and a PE ratio of -4.13. Tocagen Inc has a 52-week low of $8.60 and a 52-week high of $17.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.23 and a quick ratio of 5.23.
Tocagen (NASDAQ:TOCA) last announced its earnings results on Thursday, March 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.02). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative net margin of 94,948.78% and a negative return on equity of 145.76%. analysts anticipate that Tocagen Inc will post -2.3 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Tocagen Inc (TOCA) Shares Bought by California State Teachers Retirement System” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/09/tocagen-inc-toca-shares-bought-by-california-state-teachers-retirement-system.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.